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Polo-Like Kinases (PLKs) are central players of mitotic progression in Eukaryotes. Given the 
intimate relationship between cell cycle progression and cancer development, PLKs in general 
and PLK1 in particular have been thoroughly studied as biomarkers and potential therapeutic 
targets in oncology. The oncogenic properties of PLK1 overexpression across different types of 
human cancers are attributed to its roles in promoting mitotic entry, centrosome maturation, 
spindle assembly and cytokinesis. While several academic labs and pharmaceutical companies 
were able to develop potent and selective inhibitors of PLK1 (PLK1i) for preclinical research, 
such compounds have reached only limited success in clinical trials despite their great 
pharmacokinetics. Even though this could be attributed to multiple causes, the housekeeping 
roles of PLK1 in both normal and cancer cells are most likely the main reason for clinical trials 
failure and withdraw due to toxicities issues. Therefore, great efforts are being invested to 
position PLK1i in the treatment of specific types of cancers with revised dosages schemes. In 
this mini review we focus on two potential niches for PLK1i that are supported by recent 
evidence: triple negative breast cancers (TNBCs) and BRCA1-deficient cancers. On the one 
hand, we recollect several lines of strong evidence indicating that TNBCs are among the 
cancers with highest PLK1 expression and sensitivity to PLK1i. These findings are encouraging 
because of the limited therapeutics options available for TNBC patients, which rely mainly on 
classic chemotherapy. On the other hand, we discuss recent evidence that unveils synthetic 
lethality induction by PLK1 inhibition in BRCA1-deficient cancers cells. This previously 
unforeseen therapeutic link between PLK1 and BRCA1 is promising because it defines novel 
therapeutic opportunities for PLK1i not only for breast cancer (i.e. TNBCs with BRCA1 
deficiencies), but also for other types of cancers with BRCA1-deficiencies, such as pancreatic 
and prostate cancers.  
 










The development of cancer is a multi-step process at which several mechanisms that 
restrict uncontrolled cell division must fail. During cancer evolution, cells acquire series of 
mutations that promote faster cell division cycles and avoid programmed cell death. In 
consequence, numerous therapeutic strategies have been developed to target cell cycle 
progression at different levels. A particularly successful case are microtubule-targeting agents, 
which by disrupting microtubule dynamics induce a persistent mitotic arrest that eventually 
leads to cell death [1]. Cancer cells also frequently exhibit genomic alterations that lead to 
cyclin dependent kinases (CDK) hyperactivation, a reason that stimulated the development of 
agents to block CDKs, which trigger cell-cycle arrest at G1/S and G2/M transitions [1]. Several 
cell-cycle blocking agents have been clinically evaluated and approved for the treatment of 
different type of cancers (Table 1). Moreover, a common limitation of such agents is that they 
do not distinguish malignant cells from normal cells, and therefore patients often experience 
adverse effects, such as peripheral neuropathy, myelosuppression, neurotoxicity, nausea, 
diarrhea, vomiting, constipation, anemia, neutropenia, fatigue [2–12]. Thus, a current 
challenge in this area is to develop therapies to target cell-cycle features that are distinctive to 
tumor cells. 
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on of CDK6[34] 
MDR: multidrug resistance; ERK: extracellular-signal-regulated kinase; PI3K: phosphatidylinositol 3-kinase; AKT: protein kinase B; RB1:  
RB transcriptional corepressor 1. 
Identification of Polo Like Kinases as therapeutic targets 
In the late 80’s, drosophila mutants at the “Polo” locus defined a direct relationship 
between the gene coded at this locus and the correct assembly of spindle poles [35]. Later on, 
it was found that the Polo gene encodes a protein with an amino-terminal domain 
homologous to a serine-threonine protein kinase [36]. Concomitantly, it was observed that 
Polo transcripts are abundant in tissues in which there is extensive mitotic activity [36], further 
supporting the critical role of this kinase in mitotic progression. A family of similar serine-
threonine kinase was found to be highly conserved from yeast to humans, yet homologs for 
these kinases were not found in bacteria, archae or plants [37]. Given to its relationship with 
the Polo genes, this family was named Polo-Like Kinases (PLKs).  
Mammalian cells have at least five PLKs: PLK1, PLK2, PLK3, PLK4 and PLK5 [38]. PLKs 
contain an N-terminal serine-threonine kinase domain (except PLK5) connected by a short 
linker to a C-terminal non-catalytic region characterized by the presence of 2 polo boxes (with 









the polo-box domain (PBD) [37]. These proteins are important regulators of multiple functions 
during mitosis, including M-phase entry, the G2/M DNA damage checkpoint, centrosomes 
biogenesis and the coordination of cytokinesis [40–42]. Such plethora of mitotic functions 
underlines the pivotal role of PLK for cell cycle progression. 
Among mammalian PLKs, PLK1 is the most thoroughly studied family member. PLK1 has 
several regulatory roles during the cell cycle, such as mitotic entry, centrosome maturation, 
spindle assembly and cytokinesis [43,44]. Interestingly, PLK1 mutations are extremely rare in 
human cancers [45] and PLK1 complete ablation by CRISPR triggered lethality in more than 700 
cell lines tested in the Cancer Dependency Map Project 
(https://depmap.org/portal/gene/PLK1?tab=overview), thus indicating its critical 
housekeeping roles in cell survival. However, the overexpression of PLK1wt is linked to 
oncogenesis by the promotion of chromosome instability and aneuploidy [46], which is 
triggered by defects in the mitotic checkpoint [47]. Elevated expression of PLK1 is observed in 
non-small-cell lung cancer, head and neck cancers, esophageal and gastric cancers, 
melanomas, breast, ovarian, endometrial, colorectal, thyroid and many other types of cancers 
(Figure 1) [48,49]. In most cases PLK1 overexpression correlates with cancer aggressiveness 
and worse prognosis [49–51]. Therefore, PLK1 was postulated as a valuable diagnostic 
biomarker in several types of cancers [49]. Moreover, initial evidence indicating that this 
protein promote tumor development [52] also quickly positioned PLK1 as a promising 
therapeutic target. In fact, PLK1 inhibition with small interfering RNAs and small molecules is 
known to trigger mitotic arrest, proliferation impairment, apoptosis and tumor growth 
inhibition [53–59].  
Many Academic Labs and Pharmaceutical Companies have established drug 
development programs to design potent and selective PLK1 inhibitors (PLK1i). Nonetheless, 
most of molecules that reached preclinical success and continued towards Phase I clinical 
trials, failed at this stage due to toxicity issues. The reported adverse effects associated to PLK1 
inhibitors treatment include hematological alterations such as anemia, neutropenia and 
thrombocytopenia, as well as gastrointestinal events (Table 2). Additionally, serious defects in 
arterial structure that leads to aortic rupture and lethality was described in Plk1 +/- mice and 
mice treated with PLK1 inhibitors [60], which reinforces the need for caution when PLK1 
inhibitors are used in therapeutic schemes. Also, the confirmation of target specificity might be 
crucial before further clinical development of PLK1 inhibitors. In fact, Rigosertib (ON1910 - 
Onconova Therapeutics), which was initially identified as a selective PLK1 inhibitor, was later 









Therefore, its underlying antitumoral mechanism remains controversial. Onconova 
Therapeutics currently attributes the therapeutic effects of Rigosertib to its RAS-mimetic 
properties, which is in Phase III trials for the treatment of Myelodysplastic syndromes 
(https://www.onconova.com/pipeline/#tab-id-2). 
Some Phase I clinical trials with PLK1 inhibitors were successful for the treatment of a 
particular set of malignancies and moved forward to Phase II and even Phase III studies (Table 
2). Nonetheless, the results of these completed studies show that treatment was not  as 
effective as expected when used as second or third lines of therapy [64–73]. Only a few 
patients displayed disease stabilization, indicating that further exploration of these therapeutic 
 
Figure 1: PLK1 RNA expression levels in cancer patients from the TCGA. Patient database analysis 
performed in 33 Cancer types. Boxplots showing PLK1 mRNA levels (expressed as log2 - CPM) in all 
tumor samples from The Cancer Genome Atlas (TCGA) provisional database 
(https://www.cancer.gov/tcga). RNA expression levels were normalized using the upper quartile 
method. Red dots represent outliers. The plot was performed using RStudio Version 1.2.1335. TCGA 
Abbreviations for each cancer type: PCPG: Pheochromocytoma and Paraganglioma (n = 178); THCA: 
Thyroid Carcinoma  (n = 505); KICH: Kidney Chromophobe (n = 66); PRAD: Prostate Adenocarcinoma 
(n = 497); KIRP: Kidney Renal Papillary Cell Carcinoma (n = 290); KIRC: Kidney Renal Clear Cell 
Carcinoma (n = 534); LGG: Lower Grade Glioma (n = 516); LIHC: Liver Hepatocellular Carcinoma (n = 
370); UVM: Uveal Melanoma (n = 79); ACC: Adrenocortical Carcinoma (n = 79); PAAD: Pancreatic 
Adenocarcinoma (n = 177); CHOL: Cholangiocarcinoma (n = 36); MESO: Mesothelioma (n = 87); 
LUAD: Lung Adenocarcinoma (n = 514); BRCA: Breast Invasive Carcinoma (n = 1095); GBM: 
Glioblastoma Multiforme (n = 155); SARC: Sarcoma (n = 259); LAML: Acute Myeloid Leukemia (n = 
173); SKCM: Skin Cutaneous Melanoma (n = 103); THYM: Thymoma (n = 119); UCEC: Uterine Corpus 
Endometrial Carcinoma (n = 175); BLCA: Bladder Urothelial Carcinoma (n = 407); LUSC: Lung 
Squamous Cell Carcinoma (n = 502); HNSC: Head and Neck Squamous Cell Carcinoma (n = 520); 
READ: Rectum Adenocarcinoma (n = 94); UCS: Uterine Carcinoma (n = 57); STAD: Stomach 
Adenocarcinoma (n = 415); OV: Ovarian Serous Cystadenocarcinoma (n = 305); ESCA: Esophageal 
Carcinoma (n = 183); COAD: Colon Adenocarcinoma (n = 285); CESC: Cervical Squamous and 
Endocervical Adenocarcinomas (n = 304); TGCT: Testicular Germ Cell Tumors (n = 150); DLBC: Diffuse 








schemes is necessary. In fact, the most successful PLK1 inhibitors to date: Volasertib and 
Onvansertib, which reached FDA´s “breakthrough therapy” and “Orphan drug” denominations 
respectively, are still struggling to find the optimal niches in clinical studies. It is clear that 
future research should focus on how the efficacy of PLK1 inhibitors is affected by different 
genetic backgrounds, or whether combinations with standard therapies could expand their 
therapeutic opportunities. In the following sections we revise several lines of recent evidence 
indicating that triple negative breast cancers, as well as cancers bearing BRCA1 deficiencies, 
display a remarkable sensitivity to PLK1 inhibitors. 
Table 2. Polo-like kinases 1 inhibitors 
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Finding therapeutics niches for PLK1 inhibitors: triple negative breast cancers 
In breast cancer (BC) patients, high PLK1 levels are significantly associated with larger 
tumor size, higher pathological grading, lymph node metastasis and worse overall survival, 
thus establishing PLK1 expression as biomarker of poor prognosis in BC [78]. Noteworthy, even 
for Luminal A cancers, which are considered less aggressive, higher levels of PLK1 expression 
are associated with poor prognosis [79]. Triple-negative breast cancer (TNBC) is considered the 
most aggressive type of BC. This is mainly because of the lack of available targeted therapies, 
being standard chemotherapy the only course of treatment [80]. 
 In the search for novel therapeutic targets for TNBC, integrated network analysis 
coupled with machine learning identified a list of differentially expressed genes associated 
with TNBC. Not surprisingly, key genes identified were enriched in cell cycle progression and 
mitotic cell division: including AURKB, CCNB2, CDC20, CCND1, TGFB3, SKP1, SKP2, MYC, and 
PLK1 [81]. Interestingly, despite the great success of mitotic poisons in BC treatment, the 
mitotic spindle was the only mitotic target with successful therapeutic intervention for 
decades (Table 1). This is the case of Paclitaxel (Taxol by Bristol-Myers-Squibb), which prevents 
completion of mitosis through binding to the β-subunit of tubulin, resulting in the formation of 
non-functional microtubule bundles, that arrest cells at G2/M [82]. Paclitaxel is the most 
widely used drug as monotherapy or in combination therapy for TNBC [83]. Therefore, the 
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Clinical trials are indicated using the clinical trials.gov identifier. EORTC: European Organization for Research and 








blockade of mitotic progression by the inhibition of overexpressed mitotic kinases (AURKs, 
PLKs) represents an appealing approach to target the same biological process with the 
potential of delivering more selective outcomes against tumor cells. Strikingly, it was shown 
that PLK1 inhibition induces G2/M arrest and creates polyploid cell populations, leading to 
significant growth inhibition and triggering apoptosis in multiple TNBC cell lines [84–86]. A 
related intriguing finding was that the inhibition of PLK1 induces apoptosis in a TNBC cell 
subpopulation with stem cell properties known as tumor-initiating cells (TICs) [84]. It has been 
proposed that TICs are resistant to traditional chemotherapies and are considered responsible 
for breast cancer relapse [87–90]. Thus, targeting PLK1 emerges as a promising therapeutic 
strategy for the treatment of TNBC. 
Retrospective analysis of The Cancer Genome Atlas (TCGA) database shows remarkably 
higher levels of PLK1 expression in BC solid tumors in comparison to the normal surrounding 
mammary tissues obtained in biopsies (Fig. 2A). Strikingly, PLK1 levels are higher in Basal-like 
tumors when comparing pam50 subtypes (Fig. 2B), and higher when comparing TNBC vs. non-
TNBC samples (Fig. 2C) [45]. These findings are in agreement with previous reports showing 
increased PLK1 expression in TNBC cell lines and patient samples [85,86]. Such similar findings 
reported by different groups strongly support the notion that this type of BC patients, which 
are characterized by limited therapeutic options, could benefit with therapeutic schemes 
involving PLK1 inhibition.  
 
Figure 2: PLK1 RNA expression levels in breast cancer patients from the TCGA. Analyses performed 
using data generated by the TCGA Research Network (https://www.cancer.gov/tcga). A. Boxplots 
showing PLK1 gene expression (as log2 - CPM) in tumor-adjacent normal tissue compared to breast 
cancer solid tumor sample from the same patient. Dotted lines connect paired samples, n = 104. B. 
PLK1 gene expression (as log2 - CPM) across pam50 breast cancer subtypes: Luminal A (LumA, n = 
322), Luminal B (LumB, n = 250), HER2-enriched (Her2, n = 158) and Basal-like (Basal, n = 236). C. 
PLK1 gene expression (as log2 - CPM) in TNBC (n = 112) compared to non-TNBC (n = 854) breast 
cancer patients. Red dots represent outliers. Plots and statistical analyses were performed using 
RStudio Version 1.2.1335, applying Student's t-test for paired samples in A (***p < 0.001); One-way 
ANOVA (ANalysis Of VAriance) with post-hoc Tukey HSD test in B (Basal vs any condition ***p < 









Finding therapeutics niches for PLK1 inhibitors: BRCA1-deficient cancers 
BRCA1 and BRCA2 are well-recognized tumor suppressor genes that were initially 
identified in hereditary types of breast and ovarian cancers [91]. However, a growing set of 
recent evidence shows that mutations or epigenetic downregulation of BRCA genes are also 
frequently found in sporadic cancers, being the underlying genome instability the driving force 
of tumorigenesis [92,93]. Besides its well characterized role in homology-directed repair, 
BRCA1 also participates in diverse biological processes, including the assembly of the mitotic 
spindle [94–96]. Several genotoxic agents stimulate BRCA1-PLK1 interaction, where BRCA1 
plays a role in downregulating the kinase activity of PLK1 [97]. In fact, PLK1 activity is increased 
in BRCA1-depleted cells [45,97]. Consequently, it is tempting to speculate that BC patients with 
aberrant expression of BRCA1 should become more sensitive to PLK1 inhibitors as 
monotherapy or in combination with DNA damaging agents. In line with such hypothesis, an 
unbiased screening targeting the human kinome recently performed in our lab unveiled that 
PLK1 inhibitors trigger strong synthetic lethality in BRCA1-deficient cells in a dose-range where 
they depict little cytotoxic effect in BRCA1-proficient cells [45]. In this study, we did not find 
acute genomic instability induction by the PLK inhibitor Volasertib within the synthetic lethal 
dose-range, thus suggesting that this type of treatment might induce a “clean” type of 
antitumoral response in BRCA1-deficient cells, attenuating genomic instability and delaying the 
acquisition of resistance mechanisms in cancer cells [45]. Taken together with the evidence 
discussed in the previous section, these findings stimulate the design of future clinical trials 
focused on TNBC patients that consider BRCA1 status as a stratification marker. Such strategic 
patient cohort harbors the two biomarkers of therapeutic response to PLK1 inhibitors 
described herein: absence of ER/PR/HER2 expression and BRCA1-deficiency. 
This emerging therapeutic field might expand the use of PLK1 inhibitors in other BRCA1-
deficient malignancies besides TNBCs. Just a few years ago, BRCA-deficiencies were considered 
an exclusive feature of breast and ovarian familial cancers (1-5%) [98]. However, current 
estimations using whole genome sequencing unveiled that BRCA-like phenotypes (also 
referred as BRCAness) are found in at least 22% of breast cancers, while in ovarian these 
proportion seems to be exceptionally higher, reaching up to 60% of the patients [99]. 
Nonetheless, it is perhaps more remarkable the increasing evidence of cancers in other organs 
that also bear HR-deficiencies. Whole exome sequencing and transcriptomic profiling of 
castration-resistant prostate cancer (CRPC) samples predicts that more than 19% of these 
tumors bear at least one mutation in a BRCAness-associated gene, including BRCA1, BRCA2, 









adenocarcinoma (PDAC) demonstrated that 24% possessed either a germline or a somatic 
mutation in BRCA1, BRCA2 or PALB2 [101]. Even though more detailed genomic analyses are 
required to determine the actual penetrance of BRCA1-deficiencies in such different cancer 
types, it is quite clear that BRCA1 alteration is not restricted to breast and ovarian cancers, and 
therefore therapeutic approaches based on synthetic lethality induction by PLK1i would also 
potentially benefit other patient cohorts. Moreover, future in-depth analysis of PLK1 
interactions with other molecular pathways might expand the use of PLK1i to other contexts. 
For example, previous studies show a reduced sensitivity of cancer cells expressing wild-type 
TP53 to PLK1 inhibition compared with TP53-mutant cells [102,103]. Likewise, it has been 
shown that cancers with activated KRAS are addicted to PLK1 activity, suggesting that KRAS-
mutated malignancies might also be susceptible to PLK1 inhibition [104]. Furthermore, a study 
revealed that the depletion of the tumor suppressor PTEN induces increased expression of 
PLK1 in prostate cancer cells, being PTEN-null cells more sensitive to PLK1 inhibition in 
comparison with PTEN-proficient prostate cells [105]. Since the loss of PTEN is a hallmark of 
TNBC [106–108], these findings might be in line with the increased sensitivity of this subgroup 
of breast cancer cells to PLK1 inhibitors. 
 
PARP and PLK1 inhibitors: complementary or alternative? 
In the last couple of years, we have witnessed the great success of poly (adenosine 
diphosphate (ADP)-ribosyl) polymerase inhibitors (PARPi), which are currently used in the clinic 
as a synthetic lethal strategy to treat malignancies with homology-directed repair deficiencies, 
such as breast and ovarian cancers harboring mutations in BRCA genes [109]. The emergence 
of PLK1 inhibition as a strategy to treat TNBC and BRCA1-deificient cancers opens the 
discussion of whether such strategy can be complementary and/or alternative to PARPi. The 
available evidence indicates that PARPi and PLK1i work through different molecular 
mechanisms [45,110–112].For instance, PLK1 inhibition shows only mild synthetic lethal 
activity with BRCA2-deficient cells [45], while PARP inhibition induces synthetic lethality both 
with BRCA1 and BRCA2, as well as with other related proteins that trigger homology-directed 
repair deficiencies [113]. In addition, while some TNBCs display sensitivity to PARP inhibition 
[114], this response does not seems to be selective for all types of TNBCs, in contrast to the 
more general link found between this cancer subtype and PLK1i sensitivity [45,84–86]. 
Therefore, combinatorial, sequential and alternative approaches can be envisioned for PLK1i 
and PARPi in the clinic. A particularly interesting cancer cohort that might benefit from PLK1i is 









field with little clinical information available and it can arise from different types of alterations 
in cancer cells [115]. Importantly, resistance to platinum-based chemotherapies is a strong 
predictor for PARPi resistance, indicating that they probably share common mechanisms of 
action [116]. One of the proposed mechanisms involves elevated expression of ABC 
transporters, such as the P-glycoprotein efflux pump (also known as PgP, ABCB1 and MDR1) 
[117], which reduces the efficacy of a number of drugs by enhancing the intracellular-to-
extracellular translocation of small molecules. An additional mechanism that might explain at 
least 50% of the cases of acquired resistance to PARPi are secondary mutations in other genes, 
which restore HR proficiency [113]. Since these cancer cells are still mutant for BRCA1, despite 




In this review, we aimed to summarize the state of the art of PLK1 inhibitors and their 
potential clinical applications. To our understanding, the exciting recent findings regarding 
their robust and selective activity against TNBCs and BRCA1-deficient cancers should trigger a 
renewed interest for this set of drugs, which might be used as monotherapy or in combination 
with other therapeutic agents to treat these types of malignancies with limited therapeutics 
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